<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36578498</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The intragraft vascularized bone marrow induces secondary donor-specific mystacial pad allograft tolerance.</ArticleTitle><Pagination><StartPage>1059271</StartPage><MedlinePgn>1059271</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1059271</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1059271</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Vascularized bone marrow (VBM) is essential in tolerance induction through chimerism. We hypothesized that the inclusion of VBM contributes to the induction of mystacial pad allotransplantation tolerance.</AbstractText><AbstractText Label="METHOD">In this study, 19 VBM, nine mystacial pad, and six sequential VBM and mystacial pad allografts were transplanted from Brown Norway (BN) rats to Lewis (LEW) rats to test our hypothesis. The VBM recipients were divided into antilymphocyte serum (ALS) monotherapy group (two doses of ALS on day 3 pretransplantation and day 1 posttransplantation), immunosuppressant group [a week of 2 mg/kg/day tacrolimus (Tac) and 3 weeks of 3 mg/kg/day rapamycin (RPM)], and combined therapy group. The mystacial pad recipients were divided into VBM and non-VBM transplantation groups, and both groups were treated with an immunosuppression regimen that consists of ALS, Tac, and RPM. For the recipients of sequential VBM and mystacial pad allotransplantations, additional Tac was given 1 week after mystacial pad transplantation. Allograft survival, donor-specific tolerance, and chimerism level were evaluated.</AbstractText><AbstractText Label="RESULTS">With the administration of ALS and short-term Tac and RPM treatments, VBM recipients demonstrated long-term graft survival (&gt;120 days) with persistent chimerism for 30 days. CD3<sup>+</sup> T cells from tolerant rats showed donor-specific hyporesponsiveness and tolerance to donor skin grafts but not to third-party counterparts. Furthermore, mystacial pad graft recipients with VBM transplantation exhibited a higher allograft survival rate than those without VBM transplantation [median survival time (MST) &gt;90 days vs. 70 days, <i>p</i> &lt; 0.05].</AbstractText><AbstractText Label="CONCLUSION">This study demonstrated that VBM transplantation is an efficient strategy to induce and maintain donor-specific tolerance for an osseous-free allograft.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Lin, Anggelia, Cheng, Hsieh, Chuang, Yang and Lin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Cheng-Hung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anggelia</LastName><ForeName>Madonna Rica</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Hui-Yun</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Yun-Huan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Epworth Eastern Hospital, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Wen-Yu</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Pathology, Chang Gung Memorial Hospital, Chang Gung Medical College and Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Huang-Yu</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chih-Hung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000961">Antilymphocyte Serum</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber><NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001853" MajorTopicYN="Y">Bone Marrow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023001" MajorTopicYN="N">Transplantation Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011917" MajorTopicYN="N">Rats, Inbred Lew</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011914" MajorTopicYN="N">Rats, Inbred BN</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000961" MajorTopicYN="N">Antilymphocyte Serum</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">donor-specific</Keyword><Keyword MajorTopicYN="N">mystacial pad</Keyword><Keyword MajorTopicYN="N">tolerance</Keyword><Keyword MajorTopicYN="N">vascularized bone marrow transplantation</Keyword><Keyword MajorTopicYN="N">vascularized composite allotransplantation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36578498</ArticleId><ArticleId IdType="pmc">PMC9791084</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1059271</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Madani H, Hettiaratchy S, Clarke A, Butler PE. Immunosuppression in an emerging field of plastic reconstructive surgery: Composite tissue allotransplantation. J Plast Reconstr Aesthet Surg (2008) 61(3):245&#x2013;9. doi:&#xa0;10.1016/j.bjps.2007.10.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2007.10.048</ArticleId><ArticleId IdType="pubmed">18083645</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda H, Ikeguchi R, Aoyama T, Ohta S, Noguchi T, Kaizawa Y, et al. . Relative antigenicity of components in vascularized composite allotransplants: An experimental study of micrornas expression in rat hind limb transplantation model. Microsurgery (2019) 39(4):340&#x2013;8. doi:&#xa0;10.1002/micr.30408</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/micr.30408</ArticleId><ArticleId IdType="pubmed">30556929</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. Kidney Int (2001) 59(1):3&#x2013;16. doi:&#xa0;10.1046/j.1523-1755.2001.00460.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2001.00460.x</ArticleId><ArticleId IdType="pubmed">11135052</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant (2006) 6(5 Pt 1):876&#x2013;83. doi:&#xa0;10.1111/j.1600-6143.2006.01259.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2006.01259.x</ArticleId><ArticleId IdType="pubmed">16611323</ArticleId></ArticleIdList></Reference><Reference><Citation>Seung E, Iwakoshi N, Woda BA, Markees TG, Mordes JP, Rossini AA, et al. . Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-Cd154 antibody: Absence of graft-Versus-Host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted Nod/Lt mice. Blood (2000) 95(6):2175&#x2013;82. doi:&#xa0;10.1182/blood.V95.6.2175</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V95.6.2175</ArticleId><ArticleId IdType="pubmed">10706892</ArticleId></ArticleIdList></Reference><Reference><Citation>Pree I, Wekerle T. Inducing mixed chimerism and transplantation tolerance through allogeneic bone marrow transplantation with costimulation blockade. Methods Mol Biol (2007) 380:391&#x2013;403. doi:&#xa0;10.1007/978-1-59745-395-0_25</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-395-0_25</ArticleId><ArticleId IdType="pubmed">17876108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, et al. . Allogeneic bone marrow transplantation with Co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med (2000) 6(4):464&#x2013;9. doi:&#xa0;10.1038/74731</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/74731</ArticleId><ArticleId IdType="pubmed">10742157</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth RN, Rodriguez ED, Mundinger GS, Nam AJ, Ha JS, Hui-Chou H, et al. . Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. Am J Transplant (2011) 11(7):1407&#x2013;16. doi:&#xa0;10.1111/j.1600-6143.2011.03551.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2011.03551.x</ArticleId><ArticleId IdType="pubmed">21668624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CH, Anggelia MR, Cheng HY, Wang AYL, Chuang WY, Lin CH, et al. . The intragraft vascularized bone marrow component plays a critical role in tolerance induction after reconstructive transplantation. Cell Mol Immunol (2021) 18(2):363&#x2013;73. doi:&#xa0;10.1038/s41423-019-0325-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-019-0325-y</ArticleId><ArticleId IdType="pmc">PMC8027407</ArticleId><ArticleId IdType="pubmed">31754236</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-Versus-Host disease after bone marrow transplant. Annu Rev Med (2003) 54:29&#x2013;52. doi:&#xa0;10.1146/annurev.med.54.101601.152339</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.med.54.101601.152339</ArticleId><ArticleId IdType="pubmed">12359826</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemionow M, Kulahci Y. Experimental models of composite tissue allograft transplants. Semin Plast Surg (2007) 21(4):205&#x2013;12. doi:&#xa0;10.1055/s-2007-991190</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-991190</ArticleId><ArticleId IdType="pmc">PMC2884850</ArticleId><ArticleId IdType="pubmed">20567673</ArticleId></ArticleIdList></Reference><Reference><Citation>Landin L, Cavadas PC, Gonzalez E, Caballero-Hidalgo A, Rodriguez-Perez JC. Sensorimotor recovery after partial facial (Mystacial pad) transplantation in rats. Ann Plast Surg (2009) 63(4):428&#x2013;35. doi:&#xa0;10.1097/SAP.0b013e31819031ef</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SAP.0b013e31819031ef</ArticleId><ArticleId IdType="pubmed">19745713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulahci Y, Siemionow M. A new composite Hemiface/Mandible/Tongue transplantation model in rats. Ann Plast Surg (2010) 64(1):114&#x2013;21. doi:&#xa0;10.1097/SAP.0b013e3181a20cca</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SAP.0b013e3181a20cca</ArticleId><ArticleId IdType="pubmed">20023458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulahci Y, Altuntas SH, Karagoz H, Cwykiel JM, Zor F, Siemionow M. A new total hemiface allotransplantation model in rats. Microsurgery (2016) 36(3):230&#x2013;8. doi:&#xa0;10.1002/micr.22527</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/micr.22527</ArticleId><ArticleId IdType="pubmed">26797916</ArticleId></ArticleIdList></Reference><Reference><Citation>Unal S, Agaoglu G, Zins J, Siemionow M. New surgical approach in facial transplantation extends survival of allograft recipients. Ann Plast Surg (2005) 55(3):297&#x2013;303. doi:&#xa0;10.1097/01.sap.0000168693.25306.79</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sap.0000168693.25306.79</ArticleId><ArticleId IdType="pubmed">16106171</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamson LA, Huang WC, Breidenbach WC, Rahhal D, Xu H, Huang Y, et al. . A modified model of hindlimb osteomyocutaneous flap for the study of tolerance to composite tissue allografts. Microsurgery (2007) 27(7):630&#x2013;6. doi:&#xa0;10.1002/micr.20414</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/micr.20414</ArticleId><ArticleId IdType="pubmed">17868137</ArticleId></ArticleIdList></Reference><Reference><Citation>Sucher R, Lin CH, Zanoun R, Atsina KK, Weinstock M, Pulikkotil B, et al. . Mouse hind limb transplantation: A new composite tissue allotransplantation model using nonsuture supermicrosurgery. Transplantation (2010) 90(12):1374&#x2013;80. doi:&#xa0;10.1097/TP.0b013e3181ff4fc3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e3181ff4fc3</ArticleId><ArticleId IdType="pubmed">21076369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir S, Bozkurt M, Krokowicz L, Klimczak A, Siemionow M. Correlation of chimerism with graft size and revascularization in vascularized and nonvascularized skin allografts. Ann Plast Surg (2009) 62(4):430&#x2013;8. doi:&#xa0;10.1097/SAP.0b013e3181877ad7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SAP.0b013e3181877ad7</ArticleId><ArticleId IdType="pubmed">19325352</ArticleId></ArticleIdList></Reference><Reference><Citation>Oura T, Hotta K, Cosimi AB, Kawai T. Transient mixed chimerism for allograft tolerance. Chimerism (2015) 6(1-2):21&#x2013;6. doi:&#xa0;10.1080/19381956.2015.1111975</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19381956.2015.1111975</ArticleId><ArticleId IdType="pmc">PMC5064472</ArticleId><ArticleId IdType="pubmed">26517761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham SM, Rao AS, Zeevi A, Kormos RL, McCurry KR, Hattler BG, et al. . A clinical trial combining donor bone marrow infusion and heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg (2000) 119(4 Pt 1):673&#x2013;81. doi:&#xa0;10.1016/S0022-5223(00)70001-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(00)70001-8</ArticleId><ArticleId IdType="pmc">PMC2958691</ArticleId><ArticleId IdType="pubmed">10733755</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Wu Y, Xin K, Wang JJ, Xu H, Ildstad ST, et al. . Delayed donor bone marrow infusion induces liver transplant tolerance. Transplantation (2017) 101(5):1056&#x2013;66. doi:&#xa0;10.1097/TP.0000000000001684</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000001684</ArticleId><ArticleId IdType="pubmed">28187014</ArticleId></ArticleIdList></Reference><Reference><Citation>Szade K, Gulati GS, Chan CKF, Kao KS, Miyanishi M, Marjon KD, et al. . Where hematopoietic stem cells live: The bone marrow niche. Antioxid Redox Signal (2018) 29(2):191&#x2013;204. doi:&#xa0;10.1089/ars.2017.7419</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7419</ArticleId><ArticleId IdType="pmc">PMC6016729</ArticleId><ArticleId IdType="pubmed">29113449</ArticleId></ArticleIdList></Reference><Reference><Citation>Anggelia MR, Cheng HY, Lai PC, Hsieh YH, Lin CH, Lin CH. Cell therapy in vascularized composite allotransplantation. BioMed J (2022) 45(3):454&#x2013;64. doi:&#xa0;10.1016/j.bj.2022.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2022.01.005</ArticleId><ArticleId IdType="pmc">PMC9422067</ArticleId><ArticleId IdType="pubmed">35042019</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay K, Fine RN. Solid organ transplantation following end-organ failure in recipients of hematopoietic stem cell transplantation in children. Pediatr Nephrol (2014) 29(8):1337&#x2013;47. doi:&#xa0;10.1007/s00467-013-2587-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-013-2587-4</ArticleId><ArticleId IdType="pubmed">23949630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CH, Wang YL, Anggelia MR, Chuang WY, Cheng HY, Mao Q, et al. . Combined anti-Cd154/Ctla4ig costimulation blockade-based therapy induces donor-specific tolerance to vascularized osteomyocutaneous allografts. Am J Transplant (2016) 16(7):2030&#x2013;41. doi:&#xa0;10.1111/ajt.13694</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.13694</ArticleId><ArticleId IdType="pubmed">26914847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HY, Huang XT, Lin CF, Al Deek NF, Shih LY, Lin CH, et al. . Predicting outcomes of rat vascularized composite allotransplants through quantitative measurement of chimerism with pcr-amplified short tandem repeat. J Immunol Res (2020) 2020:9243531. doi:&#xa0;10.1155/2020/9243531</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9243531</ArticleId><ArticleId IdType="pmc">PMC7024101</ArticleId><ArticleId IdType="pubmed">32090131</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamimura K, Gao W, Maki T. Cd4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol (2006) 176(7):4125&#x2013;32. doi:&#xa0;10.4049/jimmunol.176.7.4125</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.7.4125</ArticleId><ArticleId IdType="pubmed">16547248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueckelhaus M, Fischer S, Seyda M, Bueno EM, Aycart MA, Alhefzi M, et al. . Vascularized composite allotransplantation: Current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transpl Int (2016) 29(6):655&#x2013;62. doi:&#xa0;10.1111/tri.12652</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.12652</ArticleId><ArticleId IdType="pmc">PMC4785085</ArticleId><ArticleId IdType="pubmed">26265179</ArticleId></ArticleIdList></Reference><Reference><Citation>Landin L, Cavadas PC, Gonzalez E, Rodriguez JC, Caballero A. Functional outcome after facial allograft transplantation in rats. J Plast Reconstr Aesthet Surg (2008) 61(9):1034&#x2013;43. doi:&#xa0;10.1016/j.bjps.2007.12.084</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2007.12.084</ArticleId><ArticleId IdType="pubmed">18621596</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuhaus P, Klupp J, Langrehr JM. Mtor inhibitors: An overview. Liver Transpl (2001) 7(6):473&#x2013;84. doi:&#xa0;10.1053/jlts.2001.24645</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jlts.2001.24645</ArticleId><ArticleId IdType="pubmed">11443573</ArticleId></ArticleIdList></Reference><Reference><Citation>Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin a, preserves the highly suppressive Cd27+ subset of human Cd4+Cd25+ regulatory T cells. Blood (2006) 107(3):1018&#x2013;23. doi:&#xa0;10.1182/blood-2005-07-3032</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-07-3032</ArticleId><ArticleId IdType="pubmed">16210336</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human Cd4+Cd25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 178(1):320&#x2013;9. doi:&#xa0;10.4049/jimmunol.178.1.320</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.1.320</ArticleId><ArticleId IdType="pubmed">17182569</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands Cd4+Cd25+Foxp3+ regulatory T cells. Blood (2005) 105(12):4743&#x2013;8. doi:&#xa0;10.1182/blood-2004-10-3932</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-10-3932</ArticleId><ArticleId IdType="pubmed">15746082</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional Cd4+Cd25+Foxp3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol (2006) 177(12):8338&#x2013;47. doi:&#xa0;10.4049/jimmunol.177.12.8338</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.12.8338</ArticleId><ArticleId IdType="pubmed">17142730</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilon CB, Petillon S, Naserian S, Martin GH, Badoual C, Lang P, et al. . Administration of low doses of il-2 combined to rapamycin promotes allogeneic skin graft survival in mice. Am J Transplant (2014) 14(12):2874&#x2013;82. doi:&#xa0;10.1111/ajt.12944</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.12944</ArticleId><ArticleId IdType="pubmed">25394722</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PloS One (2009) 4(6):e5994. doi:&#xa0;10.1371/journal.pone.0005994</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005994</ArticleId><ArticleId IdType="pmc">PMC2694984</ArticleId><ArticleId IdType="pubmed">19543393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrysova L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O'Garra A. Integrated T-cell receptor and costimulatory signals determine tgf-Beta-Dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol (2011) 41(5):1242&#x2013;8. doi:&#xa0;10.1002/eji.201041073</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201041073</ArticleId><ArticleId IdType="pubmed">21469110</ArticleId></ArticleIdList></Reference><Reference><Citation>Anggelia MR, Cheng HY, Chuang WY, Hsieh YH, Wang AYL, Lin CH, et al. . Unraveling the crucial roles of Foxp3+ regulatory T cells in vascularized composite allograft tolerance induction and maintenance. Transplantation (2021) 105(6):1238&#x2013;49. doi:&#xa0;10.1097/TP.0000000000003509</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003509</ArticleId><ArticleId IdType="pubmed">33141809</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher JD, Balmert SC, Zhang W, Schweizer R, Schnider JT, Komatsu C, et al. . Treg-inducing microparticles promote donor-specific tolerance in experimental vascularized composite allotransplantation. Proc Natl Acad Sci U.S.A. (2019) 116(51):25784&#x2013;9. doi:&#xa0;10.1073/pnas.1910701116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1910701116</ArticleId><ArticleId IdType="pmc">PMC6925993</ArticleId><ArticleId IdType="pubmed">31792185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang JY, Tanriver Y, Jiang S, Xue SA, Ratnasothy K, Chen D, et al. . Conferring indirect allospecificity on Cd4+Cd25+ tregs by tcr gene transfer favors transplantation tolerance in mice. J Clin Invest (2008) 118(11):3619&#x2013;28. doi:&#xa0;10.1172/JCI33185</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI33185</ArticleId><ArticleId IdType="pmc">PMC2564608</ArticleId><ArticleId IdType="pubmed">18846251</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnasothy K, Jacob J, Tung S, Boardman D, Lechler RI, Sanchez-Fueyo A, et al. . Il-2 therapy preferentially expands adoptively transferred donor-specific tregs improving skin allograft survival. Am J Transplant (2019) 19(7):2092&#x2013;100. doi:&#xa0;10.1111/ajt.15306</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15306</ArticleId><ArticleId IdType="pmc">PMC6618286</ArticleId><ArticleId IdType="pubmed">30748096</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeberger S, Gorantla VS, Brandacher G, Zeevi A, Demetris AJ, Lunz JG, et al. . Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 257(2):345&#x2013;51. doi:&#xa0;10.1097/SLA.0b013e31826d90bb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31826d90bb</ArticleId><ArticleId IdType="pmc">PMC4162482</ArticleId><ArticleId IdType="pubmed">23001085</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemionow M, Izycki D, Ozer K, Ozmen S, Klimczak A. Role of thymus in operational tolerance induction in limb allograft transplant model. Transplantation (2006) 81(11):1568&#x2013;76. doi:&#xa0;10.1097/01.tp.0000209508.37345.82</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.tp.0000209508.37345.82</ArticleId><ArticleId IdType="pubmed">16770246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt M, Klimczak A, Nasir S, Zor F, Krokowicz L, Siemionow M. Composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin allotransplantation model of bone marrow transplantation. Microsurgery (2013) 33(1):43&#x2013;50. doi:&#xa0;10.1002/micr.22023</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/micr.22023</ArticleId><ArticleId IdType="pubmed">22821819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zor F, Bozkurt M, Cwykiel J, Karagoz H, Kulahci Y, Uygur S, et al. . The effect of thymus transplantation on donor-specific chimerism in the rat model of composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin allotransplantation. Microsurgery (2020) 40(5):576&#x2013;84. doi:&#xa0;10.1002/micr.30555</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/micr.30555</ArticleId><ArticleId IdType="pubmed">31904149</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfadil S, Mi-Jeong K, Lozano MI, Oh BC, Lee WPA, Brandacher G, et al. . Optimization of intra-thymic transplantation of donor-derived thymic epithelial cells to promote lasting regulation of anti-donor reactivity. Vascularized Composite Allotransplantation (2016) 3(1-2):46&#x2013;. doi:&#xa0;10.1080/23723505.2016.1234206</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23723505.2016.1234206</ArticleId></ArticleIdList></Reference><Reference><Citation>Landin L, Cavadas PC. The mystacial pad flap: A functional facial flap in rats. Ann Plast Surg (2006) 56(1):107&#x2013;8. doi:&#xa0;10.1097/01.sap.0000192422.31718.4f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sap.0000192422.31718.4f</ArticleId><ArticleId IdType="pubmed">16374109</ArticleId></ArticleIdList></Reference><Reference><Citation>Sucher R, Lin CH, Oberhuber R, Kern B, Zheng XX, Zelger B, et al. . Hemiface allotransplantation in the mouse. Plast Reconstr Surg (2012) 129(4):867&#x2013;70. doi:&#xa0;10.1097/PRS.0b013e3182450aff</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e3182450aff</ArticleId><ArticleId IdType="pubmed">22456359</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>